MedTrace Logo

ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers

NCT06513624 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-07-25

No results posted yet for this study

Summary

This is an open-label, single-arm, investigator-initiated study conceived as a dose expansion cohort of the study D3-002, which evaluated ETC-159 in combination with pembrolizumab in solid tumors.

Conditions

  • With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

Interventions

DRUG

ETC-159

ETC-159 will be administered orally.

DRUG

Pembrolizumab

Pembrolizumab will be administered intravenously.

DRUG

Denosumab / Zoledronic Acid

Denosumab will be administrated subcutaneously. Zoledronic Acid will be administered intravenously if denosumab has no response.

Sponsors & Collaborators

  • EDDC (Experimental Drug Development Centre), A*STAR Research Entities

    collaborator OTHER_GOV

  • National University Hospital, Singapore

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-09
Primary Completion
2026-12-31
Completion
2027-06-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06513624 on ClinicalTrials.gov